All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your PsOPsA Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB and Bristol Myers Squibb: For educational content and news updates.
16-week vs 8-week guselkumab maintenance treatment in patients with plaque psoriasis: Results from the phase III GUIDE trial
| The ongoing phase IIIb GUIDE trial (NCT03818035) is assessing the safety and efficacy of guselkumab, a fully human monoclonal antibody that targets the p19 subunit of interleukin (IL)-23, in patients with moderate-to-severe plaque psoriasis.1 Results from Part 1 of this trial were reported previously by the PsOPsA Hub. In Part 2 (Week 28–68), patients from Part 1 who achieved a Psoriasis Area and Severity Index (PASI) score of 0 at both Week 20 and Week 28, or super responders (SRes), were randomized to continue guselkumab 100 mg every 8 weeks (Group 2A; n = 148) or every 16 weeks (Group 2B; n = 149).1 Non-SRes continued guselkumab every 8 weeks (Group 2C; n = 525).1 Results from Part 2 of this trial were published in JAMA Dermatology by Eyerich, et al.1 |
| Key learnings: |
|
The primary endpoint of noninferiority of guselkumab was met; extending guselkumab dosing intervals to 16 weeks was found to be noninferior to the standard 8-week regimen for maintaining disease control in SRes, with 92.6% and 91.9% of patients in Groups 2A and 2B, respectively, achieving a PASI score of <3 at Week 68 (p = 0.001). |
| The study found that both dosing schedules resulted in similar immunologic responses, including sustained reductions in skin CD8-positive tissue-resident memory T cells and serum levels of inflammatory cytokines such as IL-17A, IL-17F, and IL-22, which are crucial in psoriasis pathogenesis. |
| Guselkumab was well tolerated across both dosing regimens, with no new safety concerns identified, supporting its potential for de-escalation strategies in clinical practice. |
| These findings suggest that extending guselkumab dosing intervals could reduce treatment burden while maintaining effective long-term disease control, offering a valuable option for personalized psoriasis management. |
- Eyerich K, Asadullah K, Pinter A, et al. Noninferiority of 16-week vs 8-week guselkumab dosing in super responders for maintaining control of psoriasis: The GUIDE randomized clinical trial. JAMA Dermatol. 2024. Online ahead of print. DOI: 10.1001/jamadermatol.2024.2463
More about...
Your opinion matters
6 votes - 80 days left ...
Related articles
Newsletter
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox